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HDAC Activity Is Required for p65/RelA-Dependent
Repression of PPARd-Mediated Transactivation
in Human Keratinocytes
Lene Aarenstrup1, Esben Noerregaard Flindt1, Kristian Otkjaer2, Morten Kirkegaard1, Jens Skorstensgaard
Andersen1 and Karsten Kristiansen1
Peroxisome proliferator-activated receptors (PPARs) play a key role in differentiation, inflammation, migration,
and survival of epidermal keratinocytes. The NF-kB has long been known to play pivotal roles in immune and
inflammatory responses, and furthermore NF-kB has been implicated in the regulation of epidermal
homeostasis. Recent studies have established that p65/RelA is a potent repressor of PPARd-mediated
transactivation in human keratinocytes. In this article we further investigate the molecular mechanisms
dictating the NF-kB-dependent repression of PPARd in human keratinocytes. We demonstrate that repression is
unique to p65/RelA, as no other member of the NF-kB family had an impact on PPARd-mediated transactivation.
Interestingly, our results show that p65/RelA only represses PPARd-dependent transactivation when PPARd is
bound to DNA via its DNA-binding domain. We show that repression is sensitive to inhibition of histone
deacetylases (HDACs) by tricostatin A (TSA), suggesting that HDAC activity is indispensable for p65/RelA-
mediated repression. Accordingly, we demonstrate that a ternary complex consisting of PPARd, p65/RelA, and
HDAC1 is formed in vivo. Finally, we demonstrate that TSA relieves tumor necrosis factor-a (TNFa)-induced
repression of PPARd-mediated transactivation of the PPARd target gene adipose differentiation-related protein
(ADRP) indicating that cross-talk between PPARd and NF-kB is of biological significance in human keratinocytes.
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INTRODUCTION
Since their discovery in the early 1990s, it has become
increasingly clear that the peroxisome proliferator-activated
receptors (PPARs) are lipid sensors that critically modulate
environmental and dietary stimuli. During recent years, much
attention has been given to the role of PPARd in skin
homeostasis. The mammalian skin has a high rate of
metabolism of fatty acids and cholesterol, and hence, the
expression and function of PPARs in the skin have been
intensively studied in mouse as well as human skin (for
review see Burdick et al., 2006). In the keratinocytes of
human skin, PPARd is the predominant PPAR subtype, highly
expressed in both the basal and suprabasal layer of the
epidermis (Westergaard et al., 2003). However, in murine
epidermis, the PPARs are expressed during fetal develop-
ment, but are undetectable in adult normal epidermis except
for the hair follicles (Michalik et al., 2001). Studies using
human primary keratinocytes (HPKs) or primary keratinocytes
isolated from neonatal mice have confirmed a role for PPARd
in epidermal cell survival and differentiation (Michalik et al.,
2001; Tan et al., 2001; Westergaard et al., 2001, 2003;
Schmuth et al., 2004; Kim et al., 2006). Thus, it has been
established that ligand activation of PPARd induces the
expression of proteins required for terminal differentiation
such as involucrin, transglutaminase type 1, and small
proline-rich proteins (SPRPs) (Westergaard et al., 2001; Kim
et al., 2006).
PPARd is dramatically increased in hyperproliferative lesional
skin from psoriatic patients (Rivier et al., 1998; Westergaard
et al., 2003). Psoriasis is characterized as an inflammatory skin
disease in which the keratinocytes are hyperproliferative and
exhibit an aberrant differentiation. But despite that PPARd
agonists like lipoxygenase products are generated at high
levels in the psoriatic lesions, the pro-differentiation activities
of PPARd are apparently blunted in this epidermal disorder.
Transcription factors of the NF-kB/rel family are well-
described intracellular mediators of inflammatory responses
(for review see Xiao and Ghosh, 2005). The NF-kB family
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consists of the following five members: p65/RelA, p50, RelB,
c-rel, and p52. All the members are expressed in human
keratinocytes (Hinata et al., 2003; Takao et al., 2003;
Johansen et al., 2005). In the basal layer, p50 is mainly
localized in the cytoplasm, with few cells exhibiting nuclear
localization, whereas p65/RelA, RelB, c-rel, and p52 are
found exclusively in the cytoplasm in both the basal and
suprabasal layer (Takao et al., 2003; Westergaard et al.,
2003). Results from in vitro experiments and transgenic/
knockout mice have convincingly shown that NF-kB is
growth inhibitory in mammalian keratinocytes, but whether it
fulfils a role in normal epidermal homeostasis is still not fully
understood (Seitz et al., 1998; Gerondakis et al., 1999).
In psoriatic epidermis, an interesting and atypical recogni-
tion site-specific regulation of NF-kB binding is observed.
NF-kB binding to the P53 promoter kB site is decreased,
whereas binding to the kB site of the IL-8 promoter is
enhanced (Johansen et al., 2005). This finding and other data
suggest that the regulation of NF-kB activity in keratinocytes
in psoriatic skin may be perturbed affecting expression of
NF-kB-responsive anti-inflammatory and apoptotic genes
(Lawrence et al., 2001; Johansen et al., 2005).
In the recent years we have investigated the interplay
between the NF-kB family and PPARd in human normal
keratinocytes. It is well described that the PPARs exhibit anti-
inflammatory effects in various cell types by repressing NF-
kB-mediated transactivation (Delerive et al., 1999; Su et al.,
1999; Straus et al., 2000). However, we have demonstrated
that PPARs are unable to repress NF-kB-mediated transacti-
vation in human keratinocytes. On the contrary, we found a
strong downregulation of ligand-independent as well as
ligand-dependent PPAR-mediated transactivation by p65/
RelA (Westergaard et al., 2003). In this article we present
an analysis of NF-kB-mediated repression of PPARd-depen-
dent transactivation. We show that p65/RelA is unique
regarding its ability to repress PPARd-mediated transactiva-
tion, and that repression is only observed when PPARd is
tethered to DNA via its DNA-binding domain. We show that
a complex containing PPARd, p65/RelA, and histone
deacetylase 1 (HDAC1) can assemble in vivo, and we
demonstrate that p65/RelA-dependent repression requires
HDAC activity. Finally, we show that this type of regulation
also is observed on endogenous PPAR-responsive genes in
human keratinocytes.
RESULTS
Regulation of PPARd-dependent transactivation by NF-jB
Our previous studies using HPKs have shown that forced
expression of p65/RelA leads to a strong and dose-dependent
suppression of ligand-induced, PPARd-dependent transacti-
vation, whereas PPARs surprisingly do not repress p65/RelA-
dependent transactivation in keratinocytes (Westergaard
et al., 2003). To examine whether activation of the
endogenous NF-kB would similarly repress PPARd-depen-
dent transactivation, we treated HPKs with the highly specific
PPARd ligand, GW501516, in the absence or presence of IL-
1b. Recapitulating the results obtained with forced expression
of p65/RelA, IL-1b treatment abrogated the ability of
endogenous PPARd to activate a peroxisome proliferator
response element (PPRE)-containing reporter gene (Figure 1).
To further strengthen this finding and to confirm the
involvement of NF-kB in the IL-1b-induced repression, we
expressed the non-degradable NF-kB inhibitor, IkBaM. As
predicted, expression of IkBaM abolished IL-1b-induced
repression of PPARd-mediated transactivation and even
enhanced the level of transactivation above that observed
in cells that did not express IkBaM (Figure 1). Recent studies
have shown that IkBa physically associates with several
specific HDACs and sequesters HDAC3 in the cytoplasm of
HeLa cells and 3T3-L1 adipocytes (Viatour et al., 2003; Gao
et al., 2006), and a similar phenomenon may at least in part
explain the observed increase in the level of basal transacti-
vation in keratinocytes with forced expression of the IkBa
mutant.
We have previously shown that p50 in contrast to p65/
RelA is unable to downregulate PPARd-dependent trans-
activation (Westergaard et al., 2003). Given the fact that all
five members of the NF-kB family are expressed in
keratinocytes of the human skin, and therefore might
modulate PPARd-dependent transactivation similar to p65/
RelA, we decided to determine whether also RelB, c-rel, and/
or p52 were able to repress PPARd-mediated transactivation.
Primary keratinocytes were transiently transfected with the
PPRE-containing reporter gene together with different com-
bination of vectors expressing PPARd and the different NF-kB
members. Figure 2a shows that p65/RelA strongly and dose
dependently repressed PPARd-mediated transactivation by
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Figure 1. Activated NF-jB represses PPARd-mediated transactivation in
HPKs. HPKs were transiently transfected with the CMV-b-galactosidase
construct for normalization and the PPRE-containing Tk-Luc reporter
construct with or without pCMV-IkBaM. The cells were treated with
GW501516 and IL-1b or vehicle (0.1% DMSO) for 3 hours before harvesting.
All transfections were performed in triplicates, measured in duplicates, and
the luciferase activities were normalized to the corresponding b-galactosidase
activities. Results represent means7SD from three independent experiments.
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66% (Po4 109). Coexpression of p50 did not prevent p65/
RelA-mediated repression (results not shown). By contrast,
we found that neither forced expression of RelB nor c-rel or
p52 led to repression of the PPARd-dependent transactivation
in keratinocytes. This indicates a specific repressive action of
p65/RelA on PPARd (Figure 2c–e) and suggests that IL-1b-
mediated repression (Figure 1) most likely is executed by p65/
RelA and not other members of the NF-kB family.
In resting cells, there is no static cytoplasmic localization
of NF-kB but rather a dynamic shuttling between the nucleus
and the cytoplasm (Carlotti et al., 2000; Birbach et al., 2002).
Upon stimulation with IL-1b, NF-kB translocates to the
nucleus. Although IL-1b induced a rapid translocation of NF-
kB in keratinocytes (Figure 3), it was transient, and after
2 hours of stimulation the major pool of NF-kB again
localized to the cytoplasm. Using glutathione-S-transferase
(GST)-pull-down assays, we found that p65/RelA and PPARd
interact directly in vitro (Westergaard et al., 2003). Thus, due
to the physical interaction, the nuclear export of p65/RelA
might cause a co-translocation of PPARd in analogy with the
interesting PPARg-dependent nuclear to cytoplasmic reloca-
lization by p65/RelA in Bacteroides thetaiotaomicron-treated
Caco2 cells (Kelly et al., 2003). Such a co-translocation of
PPARd would consequently imply that the p65/RelA-
mediated abrogation of PPARd-dependent transactivation is
caused by physical removal rather than transcriptional
repression. To examine this issue, we analyzed the intracel-
lular localization of p65/RelA and PPARd in response to
stimulation of primary keratinocytes with IL-1b. Upon
administration of IL-1b, massive nuclear translocation of
p65/RelA was observed after 0.5 hour, but after 2 hours
virtually all p65/RelA had returned to the cytoplasm
(Figure 3). By contrast, within the time frame of the
experiment no alteration of the cellular localization of PPARd
could be detected by the immunofluorescence analyses,
suggesting that even though p65/RelA binds to PPARd, this
association was insufficient for sustained nuclear export of
PPARd, although we cannot formally exclude the possibility
of a nuclear export followed by a rapid import of PPARd.
In both non-treated and IL-1b-treated keratinocytes, p50
retained its nuclear localization.
Activated p65/RelA does not affect PPARd DNA binding
It has been reported that NF-kB activation diminishes DNA
binding of the PPARd/RXR heterodimer in muscle cells (Jove´
et al., 2005; Planavila et al., 2005). To study if NF-kB
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Figure 2. Only the p65/RelA subunit of NF-jB is a strong repressor of PPAR-mediated transactivation in HPKs. HPKs were cotransfected with the
PPRE-Tk-Luc and different combinations of expression vectors encoding hPPARd, (a) p65/RelA, (b) p50, (c) RelB, (d) c-rel, and (e) p52. The cells were treated
with L165041 or vehicle for 24 hours before harvesting. The SV40-b-galactosidase construct was used for normalization. All transfections were performed
in triplicates, measured in duplicates, and the luciferase activities were normalized to the corresponding b-galactosidase activities. Results represent
means7SD from three independent experiments. *P¼ 3.39 109 when cells transfected with the highest amount of p65/RelA encoding vector were compared
with p65/RelA-null-transfected cells.
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activation in human keratinocytes likewise abrogates PPARd
DNA binding, we used gel-shift analyses to examine the
effect of IL-1b-mediated activation of NF-kB on PPARd/RXR
binding to a bona fide PPARd-responsive DR-1 element
present in the human adipose differentiation-related protein
(ADRP) promoter at position 2,365 to 2,336 (Targett-
Adams et al., 2005). Nuclear extracts were prepared from
untreated keratinocytes and keratinocytes treated with IL-1b
for 30minutes. The gel-shift analysis clearly demonstrated the
expected activation of NF-kB as indicated by the strong
increase in the specific binding to an oligonucleotide
harboring the kB site of human P53 gene (Figure 4c, lanes
2 and 5). By contrast, binding to the oligonucleotide
harboring the PPARd/RXR recognition site was unaffected
by IL-1b treatment (less than 6% deviation of PPARd/RXR
binding between vehicle- and IL-1b-treated cells; Figure 4a,
Time (hours): 0 0.5 2 41
PPARδ
p65/RelA
p50
Figure 3. Intracellular localization of PPARd, p65/RelA, and p50 in HPKs after stimulation with IL-1b. HPKs were stimulated with IL-1b (10 ngml1)
for the indicated time before fixation and immunostaining of PPARd, p65/RelA, and p50. The different proteins were detected using Alexa488-conjugated
secondary antibodies and DNA was visualized by SYTOX. The magnification used was  630. One representative data set out of three independent experiments
is shown.
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Figure 4. The PPARd DNA binding to the PPARd/RXR recognition site from the human ADRP promoter is not affected by activated NF-jB. Nuclear
extracts were isolated from HPKs treated with either vehicle or IL-1b for 30minutes. (a) PPARd binding to the ADRP, (b) a mutated PPARd/RXR recognition
site, and (c) NF-kB binding to the P53 kB site were assayed by gel-shift assays. To demonstrate the specificity of the binding, unlabelled homologous
oligonucleotides were added to the binding reactions (a and c, lanes 3 and 6; b, lanes 3 and 5). Specific antibodies were added to the binding reactions to
supershift the DNA/protein complex (a and c, lanes 4 and 7). *Indicates that the PPAR binding deviates 5.1% when comparing lane 2 with lane 5. One
representative data set out of three independent experiments is shown.
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lanes 2 and 5). The specificity of the binding was demon-
strated by the absence of binding to a mutated PPARd/RXR
recognition site (Tachibana et al., 2005; Figure 4b), competi-
tion with an unlabelled probe (Figure 4a, lanes 3 and 6), and
by supershifting with a PPARd-specific antiserum (Figure 4a,
lanes 4 and 7). In conclusion, NF-kB activation did not affect
binding of PPARd/RXR to the responsive DR-1 element of the
human ADRP promoter, and thus the NF-kB-dependent
repression of PPARd-mediated transactivation did not reflect
NF-kB-dependent interference with DNA binding.
Identification of domains in PPARd and p65/RelA of importance
for functional interaction
To further elucidate the molecular basis for the interplay
between p65/RelA and PPARd, we performed a series of
experiments to delineate the functional importance of
selected regions in the two proteins. Since GST pull down
assays (Westergaard et al., 2003) have shown that PPARd
interacts strongly and specifically with the N-terminal part of
p65/RelA containing the rel homology region (RHR) in vitro,
the RHR of p65/RelA was examined for its impact on PPARd-
dependent transactivation. We found that the RHR of p65/
RelA partially repressed PPARd-dependent transactivation.
However, the strong dose-dependent repression observed
with full-length p65/RelA was not observed when RHR was
expressed, suggesting that the repression mechanisms em-
ployed by the RHR differs from those involving the full-length
p65/RelA (Figure S1 and Supplementary Materials and
Methods). To examine the importance of the different
structural domains of PPARd, we examined the effect of
p65/RelA on the transcriptional activity of full-length or a
truncated version of PPARd lacking the AB domain (PPARd(-
DAB)) fused or not to the DNA-binding domain of Gal4 using
two different reporter gene assay systems. The importance of
direct DNA binding of PPARd for p65/RelA-mediated
repression was studied using a UAS-containing reporter
construct and the different Gal4(DBD)-PPARd constructs. In
this setting direct DNA binding of PPARd via its DNA-binding
domain is not required for PPARd-dependent transactivation.
As shown in Figure 5a, the Gal4-PPARd (full length) activated
the reporter construct, but most interestingly, p65/RelA was
unable to repress the Gal4-PPARd-mediated transactivation.
Furthermore, using a construct expressing PPARd with a
deletion of the AB domain (the Gal4-PPARd(DAB) construct),
essentially the same was observed (Figure 5c). By contrast,
transactivation by full-length PPARd (Figure 5b) or PPARd
(DAB) (Figure 5d) was repressed by p65/RelA (Po0.05) when
PPARd was bound to a DR-1 PPRE via its DNA-binding
domain. Collectively, these results indicate that direct DNA
binding of PPARd via its DNA-binding domain is necessary
for repression mediated by p65/RelA.
Involvement of HDACs in p65/RelA-dependent repression of
PPARd-mediated transactivation
Histone acetylation/deacetylation is an important step in
remodelling of chromatin and regulation of global gene
expression. HDAC1 has been shown to bind directly to
the RHR of p65/RelA to regulate p65/RelA-dependent
transactivation (Ashburner et al., 2001). Since histone
deacetylation mediated by HDACs is associated with
transcriptional repression, we decided to examine whether
HDAC activity was required for p65/RelA-dependent repres-
sion of PPARd-mediated transactivation. To examine this, we
first transiently transfected HPKs with plasmids expressing
PPARd and p65/RelA and the PPRE-containing reporter
construct, and after 5 hours the cells were treated with two
different HDAC inhibitors, tricostatin A (TSA) and valproic
acid (VPA), respectively. TSA is a general inhibitor of HDACs,
whereas VPA is a selective inhibitor with preference for
inhibition of the HDAC2 isotype. Moreover, VPA has been
shown to induce proteasomal degradation of HDAC2 in
different cell lines causing an apparent induction of PPARd-
mediated transactivation (Kra¨mer et al., 2003). As shown in
Figure 6a, TSA relieved p65/RelA-mediated repression,
whereas VPA, by contrast, did not affect repression. To test
the action of the two drugs in keratinocytes, we performed
western blot analysis to detect accumulation of acetylated
histones as well as degradation of HDAC2. Consistent with
the presumed action of both TSA and VPA, the two drugs led
to an accumulation of acetylated histone H3 and histone H4
(Figure 6b). Interestingly, no VPA-induced degradation of
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Figure 5. DNA binding via the PPARd DNA-binding domain is required for
p65/RelA-mediated repression. HPKs were cotransfected with UAS-Tk-Luc
(a and c) or PPRE-Tk-Luc (b and d) and p65/RelA, and different expression
plasmids encoding Gal4-PPARd (full length) (a and b), Gal4-PPARd (DAB)
(c), and PPARd (DAB) (d), respectively, and the cells were treated with
L165041 or vehicle for 24 hours before harvesting. The SV40-b-galactosidase
construct was used for normalization. All transfections were performed in
triplicates, measured in duplicates, and the luciferase activities were
normalized to the corresponding b-galactosidase activities. Results
represent means7SD from three independent experiments. *P¼0.014,
**P¼0.00022, ***P¼0.00007, and ****P¼ 0.00001 when compared with
p65/RelA-null-transfected cells, respectively.
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HDAC2 was observed, indicating that the action of VPA on
HDAC2 in HPKs differs from that observed in other cell types
(Kra¨mer et al., 2003). In keeping with this, no synergistic
action of VPA and the PPARd agonist was detected in
transfection experiments (Figure 6a). In conclusion, the
results presented here suggest that HDAC activity was
required for p65/RelA-mediated repression of PPARd-
mediated transactivation as indicated by TSA sensitivity.
Histone acetylation status in general is important only in
the context of chromatin-organized DNA, and the extent to
which transiently transfected reporter plasmids become
packaged into nucleosome has been debated. Several lines
of evidence suggest that transfected DNA may be organized
into nucleosomes 24 hours after transfection (reviewed in
Smith and Hager, 1997), and chromatin immunoprecipitation
analyses have revealed acetylated histone associated with
plasmid DNA (Cervoni and Szyf, 2001). Thus, the need for
HDAC activity for p65/RelA-mediated repression of PPARd-
mediated transactivation may involve effects on histone
acetylation, but we cannot exclude that other regulatory
pathways were targeted by TSA.
To further investigate the interplay between HDACs and
p65/RelA in repression of PPARd-dependent transactivation,
we first examined ligand-dependent induction of known
PPARd target genes, namely SPR1A, ADRP, and FIAF
(fasting-induced adipose factor), in HPKs. Keratinocytes were
treated with 100 nM GW501516 for 6, 12, and 24 hours, and
as shown using real-time PCR, ADRP (Figure 7a) and FIAF
(data not shown) mRNAs were strongly induced. Under these
conditions the SPR1A mRNA was only induced very weakly
(data not shown). Next, we examined how the activation of
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Figure 6. TSA abolishes p65/RelA-mediated repression of PPARd-dependent transactivation. (a) HPKs were cotransfected with PPRE-Tk-Luc and different
expression plasmids encoding PPARd (20 ng) and p65/RelA. The cells were treated with L165041 or vehicle, TSA, or VPA for 24 hours before harvesting. The
SV40-b-galactosidase construct was used for normalization. All transfections were performed in triplicates, measured in duplicates, and the luciferase activities
were normalized to the corresponding b-galactosidase activities. Results represent means7SD from three independent experiments. *P¼ 0.27, **P¼ 0.018, and
***P¼5.24 106 when compared with p65/RelA-null-transfected cells, respectively. (b) HPKs were treated with TSA or VPA for the indicated time before
whole-cell preparations, and proteins were separated in SDS–polyacrylamide gels and analyzed by western blotting. TFIIB was included to confirm equal
loading and protein transfer. Bands are quantified by normalization to TFIIB and values are shown below each band.
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Figure 7. Ligand-induced ADRP expression is repressed by TNFa in the
absence but not in the presence of TSA in HPKs. (a) HPKs were treated with
GW501516 or vehicle for the time indicated before harvest. *P¼0.0008
when compared with the vehicle-treated cells (24 hours). (b) HPKs were
pretreated with TSA for 14 hours before being stimulated with L165041 for
2.5 hours and TNFa (50 mgml1) for the last 0.5 hour as illustrated in lower
part of (b). After harvesting (a and b), RNA was purified from cell extracts and
the ADRP mRNA content was assessed by real-time PCR. The mRNA level
was normalized to TBP and results represent means7SD from three
independent experiments. Significant repression in the absence of TSA,
***P¼0.0019, but no significant repression in the presence of TSA,
**P¼0.949, when compared with cells not treated with TNFa.
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endogenous NF-kB influenced the PPARd-induced expres-
sion of ADRP mRNA. For this purpose, primary keratinocytes
were treated with L165041 and tumor necrosis factor-a
(TNFa) and the expression of the ADRP mRNA was
measured. The lower part of Figure 7b illustrates the time
course of treatment, and real-time PCR analysis showed that
the ligand-induced expression of ADRP mRNA was sup-
pressed by treatment with TNFa. Furthermore, when the
keratinocytes were pretreated with TSA for 14 hours to inhibit
the activity of HDACs, the ligand-induced expression of
ADRP mRNA was no longer suppressed by TNFa, corrobor-
ating the involvement of NF-kB and HDACs in the modula-
tion of the PPARd-mediated induction of the endogenous
ADRP gene. In conclusion, at normal physiological levels
activated NF-kB and HDACs regulated the transcription of a
PPARd-responsive gene in HPKs via repression of PPARd-
dependent transactivation.
Immunoprecipitation of PPARd, p65/RelA, and HDAC1
To further examine the involvement of HDACs in p65/RelA-
mediated repression, we examined if PPARd, HDAC1, and
p65/RelA were found in the same protein complex in vivo.
For this purpose we cotransfected 293T cells with plasmids
expressing untagged or myc-tagged PPARd, p65/RelA, and
untagged or myc-tagged HDAC1 in different combinations.
The cell lysates were immunoprecipitated using sepharose
beads covalently bound to anti-myc antibodies. Figure 8a
shows that upon coexpression of myc-tagged PPARd and p65/
RelA, the immunoprecipitate contained both proteins, and
when myc-tagged PPARd and HDAC1 were coexpressed, the
HDAC1 was immunoprecipitated together with PPARd.
Furthermore, when myc-tagged PPARd, p65/RelA, and
HDAC1 were coexpressed, all three proteins were found in
the immunocomplex. Likewise, immunoprecipitation analy-
sis of myc-tagged HDAC1 coexpressed with PPARd and p65/
RelA demonstrated consistently that all three proteins were
found in the same immunoprecipitated complex (Figure 8b).
Furthermore, immunoprecipitation of lysates from cells
expressing only the RHR of p65/RelA together with myc-
PPARd and HDAC1 demonstrated that the RHR was sufficient
for interaction (Figure 8c). Further evidence that PPARd and
p65/RelA interact in vivo was obtained by mass spectrometric
analysis of immunoprecipitates from HPKs overexpressing
myc-tagged PPARd. The immunoprecititates were resolved
on an SDS–polyacrylamide gel, stained with Coomassie blue,
and the individually loaded lanes were cut into a number of
pieces. Proteins in each piece were subjected to alkylation in
situ followed by digestion with trypsin. The generated
peptides were analyzed by MS/MS (Tandem mass spectro-
metry) and proteins were identified by automated database
search. This analysis revealed unequivocally that endogenous
p65/RelA coprecipitated with PPARd (data not shown). In
summary, all immunoprecipitation studies reported here
support the notion that PPARd, p65/RelA, and HDAC1
interact physically in vivo (Figure 8).
Of note, the immunoprecipitation studies demonstrated
that HDAC1 was pulled down with PPARd without co-
expression of p65/RelA (Figure 8a and b). To examine the
possible interaction between PPARd and HDAC1 more
closely in order to establish if HDAC1 and PPARd interacts
directly or if the complex contains other bridging proteins, we
decided to make an in vitro protein–protein interaction study
using a GST pull-down assay. Full-length PPARd and GST-
HDAC1(1–432), respectively, were bacterially expressed to
avoid contamination from possible interaction/bridging part-
ners existing in conventional eukaryotic cell-free translation
systems. Figure 9a clearly demonstrates that PPARd in vitro
can interact with HDAC1 in a ligand-independent manner.
However, despite the fact that the two proteins are able to
interact, forced expression of HDAC1 did not affect PPARd-
dependent transactivation negatively (Figure 9b), suggesting
that a direct interaction of PPARd and HDAC1 per se is not
sufficient to modulate PPARd-dependent transactivation. In
fact, coexpression of HDAC1 enhanced PPARd-dependent
transactivation (P¼0.009 for the cells cotransfected with
25 ng HDAC1-encoding vector compared with the HDAC1-
null-transfected cells).
DISCUSSION
Dependent on cell types, PPARs, in particular PPARa and
PPARg, have been reported to modulate NF-kB activity by
repressing NF-kB-dependent transactivation (Ricote et al.,
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1998; Staels et al., 1998; Li et al., 2000) and the mechanisms
have been elucidated in great detail (Pascual et al., 2005).
However, studies in our laboratory have shown that the
PPARs do not repress NF-kB-dependent transactivation in
human keratinocytes (Westergaard et al., 2003). By contrast,
p65/RelA of the NF-kB family turned out to be a potent
repressor of PPAR-dependent transactivation, and further-
more, a direct physical interaction between p65/RelA and
PPARd was confirmed (Westergaard et al., 2003). In several
cases, activation of NF-kB has been shown to repress the
expression of PPARd-responsive genes (Ruan et al., 2003;
Suzawa et al., 2003; Jove´ et al., 2005; Planavila et al., 2005).
In muscle cells, activation of NF-kB enhanced interaction
between PPARd and p65/RelA, but in contrast to our findings
in keratinocytes, where IL-1b-dependent activation of NF-kB
did not affect PPARd/RXR DNA binding, a pronounced
decrease in PPARd/RXR DNA binding was observed (Jove´
et al., 2005; Planavila et al., 2005). In ST2 cells, activation of
p65/RelA was shown to inhibit binding of the PPARg/RXRa
heterodimer to the acyl-CoA PPRE by binding to the PPARg
DNA-binding domain and forming a trimeric complex
containing PGC-2 (Suzawa et al., 2003), and in HeLa cells,
p65/RelA was similarly shown to repress PPARg-mediated
transactivation (Ruan et al., 2003). Finally p65/RelA was also
reported to repress PPARa-mediated transactivation (Delerive
et al., 1999; Westergaard et al., 2003). Thus, p65/RelA-
dependent repression of PPAR-mediated transactivation
appears to be a general phenomenon, whereby inflammatory
stimuli impinge on PPAR-dependent gene expression, but the
mechanisms by which this is achieved appears to be cell type
dependent.
In this article we further investigated the molecular
mechanisms underlying the potent NF-kB-dependent
repression of PPARd-mediated transactivation in human
keratinocytes. Even though all members of the NF-kB family
are expressed in human keratinocytes, p65/RelA is unique in
its ability to repress PPARd-mediated transactivation. In HeLa
cells, p65/RelA was similarly found to be a much more potent
repressor than p50 and c-Rel, and interestingly, mutation of
Ser276 to alanine significantly diminished repression by p65/
RelA (Ruan et al., 2003). Our results indicate that the C-
terminal transactivation domain of p65/RelA at least partly is
dispensable for repression, a finding that mirrors the results
obtained for p65/RelA-dependent repression of PPARg in ST2
cells (Suzawa et al., 2003).
In the present report, we provide evidence that repression
by p65/RelA requires HDAC activity. This conclusion
was based on transient transfection experiments and
corroborated by analyzing the effects of NF-kB activation
and HDAC inhibition on the expression of endogenous
PPARd-responsive genes. The analysis of the effects on the
expression of an endogenous PPARd-responsive gene was
important as we had no formal proof that the transfected
reporter plasmids were packaged into nucleosomes. It
should be noted, although, that transiently transfected
plasmids may exhibit characteristics compatible with a
nucleosomal organization, justifying the use of transient
transfection assays for the analysis of the effect of HDACs
(Smith and Hager, 1997; Cervoni and Szyf, 2001). It is well
established that DNA binding, by affecting receptor
conformation, may exert a profound influence on cofactor-
mediated repression (Zamir et al., 1997). Here we show
that p65/RelA only is able to repress PPARd-dependent
transactivation when PPARd is bound to DNA via its DNA-
binding domain.
Using immunoprecipitation we show that a ternary
complex consisting of PPARd, p65/RelA, and HDAC1 is
formed in vivo. The protein–protein interaction data support
the notion that interaction between PPARd, p65/RelA and
HDAC has biological significance, but more comprehensive
analyses of the repressive complexes will require chromatin
immunoprecipitation-based analyses.
Even though HDAC1 is able to bind directly to PPARd, this
interaction apparently does not repress PPARd-mediated
transactivation in the absence of activated NF-kB. Thus, as
HDAC1 is able to bind to the RHR of p65/RelA, it is possible
that this interaction is necessary to activate HDAC1 or other
HDACs that may be present in the complex, similar to what
has been shown for nuclear receptor co-repressor (NCoR)-
and silencing mediator of retinoid and thyroid hormone
receptors- (SMRT)-dependent activation of HDAC3
(Guenther et al., 2001). By contrast to the well-described
silencing of unliganded PPARs, or nuclear receptors in
general, by recruitment of corepressor complexes containing
NCoR or SMRT, active suppression of ligand-activated
nuclear receptor transactivation by other HDAC containing
complexes has so far been examined less extensively. In
dendritic cells, vitamin D3/vitamin D receptor-dependent
transactivation was shown to be modulated by recruitment of
HDAC3 (Dong et al., 2005). The retinoblastoma protein was
shown to repress PPARg-mediated via recruitment of HDAC3
(Fajas et al., 2002). Interestingly, as mentioned previously,
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Figure 9. Interaction between PPARd and HDAC1 in vitro. (a) Plasmids
encoding PPARd, GST-HDAC1(1–432), or GST were expressed in E. coli, and
the bacteria lysates were incubated at 1:1 as indicated overnight, together
with glutathione–sepharose beads and L165041 or vehicle. Proteins from the
pull downs were separated on SDS–polyacrylamide gels and analyzed by
western blotting. One representative data set out of three independent
experiments is shown. (b) HPKs were transiently transfected with PPRE-Tk-Luc
and expression plasmids encoding hPPARd (20 ng) and HDAC1, and the cells
were treated with L165041 or vehicle for 24 hours before harvesting. The
SV40-b-galactosidase construct was used for normalization. All transfections
were performed in triplicates, measured in duplicates, and the luciferase
activities were normalized to the corresponding b-galactosidase activities.
Results represent means7SD from three independent experiments.
*P¼0.009 when compared with HDAC1-null-transfected cells.
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Gao et al. (2006) reported a TNFa-induced repression of
PPARg in 3T3-L1 mediated by HDAC3. In this study it was
shown that IkBa controls the nuclear translocation of
HDAC3, and thus upon TNFa-stimulated degradation of
IkBa, HDAC3 was released and translocated to the nucleus,
leading to repression of PPARg-mediated transactivation. It
remains to be established if a similar mechanism might
control the intracellular localization of HDACs in human
keratinocytes, and to further characterize the proteins
involved in p65/RelA-dependent repression of PPAR-
mediated transactivation.
As powerful regulators of specific and global gene
expression, HDACs and HDAC inhibitors have been inten-
sely investigated in recent years. Dependent on cell type,
inhibition of HDAC activity has been shown to have
antiproliferative, anti-inflammatory, and proapoptotic effects
(reviewed in Lindemann et al., 2004; Blanchard and Chipoy,
2005). Of relevance in relation to hyperproliferative skin
disorders, TSA acts growth inhibitory in HPKs by decreasing
the expression of CDK1 mRNA. Furthermore, the expression
of transglutaminase-1 mRNA was increased in response to
TSA, and after 5 days of treatment the appearance of the
keratinocytes was flattened, indicative of a differentiated
phenotype (Saunders et al., 1999). However, the data
suggested that the action of the HDAC inhibitor was not
simply to keep histones in the hyperacetylated state, and thus,
further studies are warranted in order to investigate the
molecular mechanism behind this action of the HDAC
inhibitor.
Although the anti-inflammatory role of HDAC inhibitors is
incompletely understood, it is known that HDAC inhibitors
reduce cytokine expression, and HDAC inhibitor have
therefore been discussed as agents for psoriasis therapy
(McLaughlin and La Thangue, 2004). This is particularly
interesting in relation to our findings that TSA relieves p65/
RelA-dependent repression of PPARd. Psoriasis is characte-
rized as an inflammatory disorder and the production of
inflammatory cytokines is elevated in lesional psoriatic skin.
Accordingly, is was surprising that p65/RelA maintains a
cytoplasmic localization in chronic lesional psoriatic epider-
mis, suggesting than long-term regulation of NF-kB is
dysregulated in psoriatic skin (Westergaard et al., 2003).
However it is possible that NF-kB activation may occur
during early stage of psoriasis, and if so, it is tempting to
speculate that TSA treatment in such a setting would allow
PPARd to exert its pro-differentiation and antiproliferative
activity, providing at least in part a rational for the possible
beneficial effects of TSA treatment.
MATERIALS AND METHODS
Reagents
Recombinant human IL-1b was obtained from RD Systems
(Minneapolis, MN); TSA and TNFa were purchased from Wako
(Osaka, Japan) and Calbiochem (San Diego, CA). VPA was obtained
from Sigma-Aldrich (St Louis, MO). L165041 was kindly provided by
Dr DE Moller (Merck Research Laboratories, Rathway, NJ) and
GW501516 was kindly provided by Dr MW Madsen (LEO Pharma,
Ballerup, Denmark).
Cell culture
Human keratinocytes were isolated from normal skin obtained from
adult plastic surgery operations (breast). The skin was divided into
1–1.5-cm2 pieces and incubated overnight at 41C in 10mM HEPES,
142mM NaCl, 6.7mM KCl, 0.43mM NaOH, 1mM CaCl2 containing
0.5mgml1 thermolysin (Sigma-Aldrich, St Louis, MO), pH 7.4. The
epidermis was peeled away from the underlying dermis using sterile
forceps. The keratinocytes were disaggregated into single-cell
suspension by incubating the epidermis with Dispase II (Roche,
Applied Science, Basel, Switzerland, 2.5mgml1 in Hank’s
Balanced Saline Solution; Gibco BRL, Carlsbad, CA). Keratinocytes
were cultured in Keratinocyte-SFM (Gibco BRL) supplemented with
0.03mM CaCl2 (final Ca
2þ concentration; 0.12mM), 50 mgml1
bovine pituitary extract, 5 ngml1 human recombinant epidermal
growth factor, and 5mgml1 gentamycin, in a humidified atmo-
sphere at 371C and 5% CO2.
The project was conducted according to the Declaration of
Helsinki Principles and approved by the local ethical committee.
Written consent was obtained from each donor before experiments
were initiated.
293T cells were grown in DMEM (Gibco BRL) supplemented with
10% fetal bovine serum and antibiotics (100Uml1 penicillin,
100mgml1 streptomycin sulfate). Cultures were maintained at 371C
and 5% CO2.
Plasmid constructs
pCMV-IkBaM (CLONTECHniques XV; January 2000) was kindly
provided by Dr MW Madsen (LEO Pharma, Denmark). p65-CMV2-
Flag and p50-CMV2-Flag (Stein et al., 1993) were kindly provided by
Dr A Baldwin Jr (University of North Carolina, Chapel Hill, NC),
pcDNA-RelB and pcDNA-c-rel were kindly provided by Dr S Ghosh
(Yale University School of Medicine, New Haven, CT), and pcDNA-
p52 (Xiao et al., 2001) was kindly provided by Dr A Rabson
(University of Medicine and Dentistry-Robert Wood Johnson
Medical School, Piscataway, NJ). pcDNA-PPARd and pcDNA-
PPARd(DAB) were constructed as described previously (Westergaard
et al., 2001, 2003). pcDNA-myc-mPPARd was kindly provided by
Dr E-Z Amri (Centre de Biochimie, Nice, France). pcDNA3-HDAC1,
pcDNA3myc-HDAC1, and pGEX-HDAC1(1–432) (Miska et al.,
1999; Fuks et al., 2000) were kindly provided by Dr T Kouzarides
(Wellcome/CRC Institute, Cambridge, UK). pGEX-5X-1 was pur-
chased from Amersham Biosciences (Buckinghamshire, UK). The
PPREx3-Tk-Luc and the UAS-Tk-Luc reporter constructs were kindly
provided by Dr RM Evans (Howard Hughes Medical Institute, La
Jolla, CA). pCMV-b-galactosidase (Clontech, Palo Alto, CA) and the
pSV40-b-galactosidase (Promega, Madison, WI) were used for
normalization in the transactivation assays. Construction of pQE-
11-PPARd has been described previously (Westergaard et al., 2001).
pM-GAL4-PPARd and pM-GAL4-PPARd(DAB) were cloned by
inserting the full-length mPPARd and truncated mPPARd (DAB
domain), respectively, into pM (Clontech) using BamHI and SalI.
Transactivation assays
Transient transfection of primary human keratinocytes was per-
formed in 12-well plates (Nunc, Roskilde, Denmark) using Effectene
(Qiagen, Germantown, MD). In short, cells were transfected at
approximately 30% confluency, and 5 hours after transfection the
medium was changed and the cells were treated as indicated in the
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legend to figures. The luciferase and b-galactosidase activities were
measured by standard techniques according to the manufacturer’s
instructions. The amounts of reporter and normalizing vectors used per
well were as follows: 130–160ng of PPREx3-Tk-Luc, 130ng of UAS-
Tk-Luc, 110ng pSV40-b-galactosidase, and 10–25ng pCMV-b-galac-
tosidase, and the amounts of the various expression vectors used are
stated in the figures. In all the transfections, an empty expression vector
was added to ensure equal promoter load. All transfection experiments
were repeated three times (n¼ 3), and in each experiment, all
transfections were preformed in triplicate amd measured in duplicates.
Transient transfections of HPKs for western blot analysis were
performed in 6-cm dishes using 1mg of expression plasmid.
Transient transfections of 293T cells or HPKs for immunopreci-
pitations were performed in 15-cm dishes, with equal amount (1:1:1)
of DNA (in total 10mg DNA per dish for the 293T cells or 5mg DNA
per dish for the HPKs) of the following different expression vectors
used: pcDNA-hPPARd, pcDNA-myc-PPARd, pcDNA3-HDAC1,
pcDNA3myc-HDAC1, p65-CMV2-Flag, pcDNA-p65-RHR, and
pcDNA3.1(þ ) (empty vector). The cells were transfected at 50%
confluency using standard calcium phosphate-mediated delivery for
the 293T cells and the HPKs were transfected using Effectene. Five
hours after transfection, the cells were treated with 0.5 mM L165041
for 24 hours and then harvested for immunoprecipitation.
Western blotting
Whole-cell extracts were prepared and western blotting was
performed according to standard procedures and as described in
Hansen et al. (1999). The primary antibodies used were as follows:
anti-p65 (sc-109, 1:1,000), anti-HDAC1 (sc-6298, 1:100), anti-
HDAC2 (sc-6296, 1:100), anti-HDAC3 (sc-8138, 1:200), anti-PPARg
(sc-7273, 1:1,000), anti-TFIIB (sc-225, 1:1,000) (Santa Cruz Bio-
technology, Santa Cruz, CA), anti-ac-H3 (no. 06–911, 1:500), anti-
ac-H4 (no. 06–761, 1:1,000) (Upstate Biotechnology, Lake, Placid,
NY), anti-myc (no. 1667149, 5mgml1) from Roche. Horseradish
peroxidase-conjugate secondary antibodies anti-mouse, anti-rabbit,
or anti-goat IgG (P0399, P0447, P0449, all 1:2,000) were purchased
from DAKO (Glostrup, Denmark). Stripping of membranes was
performed in 991C ddH2O for 25minutes.
RNA purification and cDNA synthesis
Total RNA from keratinocytes was isolated using TRIzol reagent
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). cDNA was generated after deoxyribonuclease I treatment by
reverse transcription (First-Strand Kit) of 1 mg of RNA primed by
random hexamers (deoxy-NTP6; Amersham Biosciences).
Real-time PCR
cDNA was analyzed by quantitative real-time PCR with an ABI-7700
PRISM real-time PCR instrument (Applied Biosystems, Foster City, CA)
using 2 SYBR Green Master Mix (Sigma-Aldrich Corp.) according to
instructions from the manufacturer. Real-time PCRs were measured in
duplicate and quantification of transcripts were performed in three
independent experiments. All quantifications were performed with
human TATA-binding protein (hTBP) as the internal standard.
The primer sequences (forward and reverse, respectively) used
were as follows:
ADRP primerset 1, 50-CGTCGATTTCTTTCTCCAGG-30 and 50-CT
GCAATTTGCGGCTCTAGC-30; ADRP primerset 2, 50-GTTCACCT
GATTGAATTTGCC-30 and 50-CGTGACTCAATGTGCTCAGC-30;
hTBP; 50-TTC CACTCACAGACTCTCAC-30 and 50-GCTCTCTTATCC
TCATGATTACC-30.
Immunoprecipitation
Transiently transfected 293T cells or HPKs were lysed on ice
(15minutes) in 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% NP-40,
1mM EDTA, 0.1% Na-deoxycholate, and 1mM Na-ortho-vanadate-
containing Complete (Roche Applied Science), and then collected
and vortexed every second minute during a next incubation on ice
(15minutes). The cell extract was centrifuged 14,000 r.p.m. for
15minutes at 41C and the cell lysate was immunoprecipitated using
anti-myc-conjugated affinity matrix (Covance Research Princeton,
NJ) overnight at 41C. The immunoprecipitate was washed three to
four times in lysis buffer and eluted by boiling in 6 SDS sample
buffer. The eluate was resolved by SDS-PAGE and analyzed by
western blotting or by mass spectrometric analysis. Cells from two
15-cm dishes were used per immunoprecipitation.
GST pull down
The bacterial expression of GST-HDAC1(1–432) fusion protein,
PPARd protein, and GST protein was performed in Escherichia coli
BL21 harboring the expression vectors pGEX-HDAC1(1–432), pQE-
11-PPARd, and pGEX-5X-1, respectively. The recombinant protein
expression was performed as described previously (Kussmann-
Gerber et al., 1999). After isolation of bacterial lysates, 2.5ml of
the each lysates were mixed (1:1) and incubate with L165041 (1 mM)
or vehicle (0.1% DMSO), and 50 ml glutathione-conjugated Sephar-
ose-4B (Amersham Biosciences, Buckinghamshire, UK) overnight at
41C. The GST pull downs were washed three times in phosphate-
buffered saline containing protease inhibitors, 1mM phenylmethyl-
sulfonyl fluoride, and Complete (Roche Applied Science, Basel,
Switzerland). The proteins were eluted by boiling in 6 SDS sample
buffer, resolved by SDS-PAGE and analyzed by western blotting.
Immunostaining
HPKs were grown in chamber slides (Nunc, Roskilde, Denmark) and
at subconfluency; the cells were treated with IL-1b (10 ngml1) for
0.5, 1, 2, and 4 hours. The cells were fixed in ice-cold 4%
formaldehyde for 10minutes, neutralized in 50mM NH4Cl for
5minutes at room temperature, and permeabilized in 70% ethanol
(EtOH) at 201C for a minimum of 15minutes. After 30minutes
incubation in blocking solution (3% BSA in phosphate-buffered
saline), samples were incubated in blocking solution containing anti-
p65 (sc-109), anti-p50 (sc-7178), and anti-PPARd antibodies
(Westergaard et al., 2001), respectively, washed, and incubated
with Alexa488-conjugated secondary antibody (Molecular Probe,
Carlsbad, CA) for 45minutes, and washed again. Samples were then
incubated in SYTOX Orange (Molecular Probes) in 100mM NaCl for
5minutes at room temperature, washed, and mounted with
fluorescent mounting medium (DakoCytomation, Glostrup, Den-
mark). Images were obtained by a multitracking laser scanning
microscopy with the LSM 510 Meta (Zeiss, Go¨ttingen, Germany).
Labelling of oligonucleotides
Oligonucleotides used for the gel-shift analysis were (only the
sequence of the upper strand is given) as follows: 50-GGGAT
TGGGGTTTTCCCCTCCC-30 containing the kB site from the human
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P53 promoter and 50-GAAGACTCTCGCCCTTTCACCTACAAAA
TG-30 containing the PPARd/RXR recognition site from the human
ADRP promoter (AL591206). The DR-1 repeat is shown in italic.
Seven picomoles annealed oligonucleotides harboring the kB site
were incubated with T4 polynucleotide kinase buffer (50mM Tris-
HCl pH 7.4, 10mM MgCl2, 5mM dithioerythritol (DTE), 1mM
spermidine), [g-32P]ATP (6,000Cimmol1 at 10mCiml1), and T4
polynucleotide kinase (New England Biolabs, Ipswich, MA) for
45minutes at 371C for labelling. The reaction was stopped by
addition of 1ml 0.5 M EDTA, and TE buffer was added to a final
volume of 100ml.
Twenty picomoles of each oligonucleotide harboring the PPARd/
RXR recognition site were labelled using T4 polynucleotide kinase
and [g-32P]ATP in T4 polynucleotide kinase buffer for 45minutes at
371C. The complementary oligonucleotides were combined and
TE-buffer was added to a final volume of 40ml. The combined
oligonucleotides were heated at 991C for 10minutes and left at room
temperature for 1hour to allow annealing. Labelled and unlabelled
oligonucleotides were separated on Microspin G-25 columns (Amer-
sham Biosciences, Buckinghamshire, UK) at 735g for 2minutes.
Gel-shift assays
The binding reactions were performed using 4mg nuclear protein
(Johansen et al., 2000) isolated from HPKs untreated or treated with
10 ngml1 IL-1b for 30minutes before harvesting. The nuclear
extracts were incubated for 20minutes at 41C in incubation buffer
(5mM MgCl2, 2.5mM EDTA, 2.5mm dithiothreitol, 250mM NaCl,
50mM Tris-HCl (pH 7.5), 20% glycerol) containing 2 mg poly(dI–dC)
and 1 mM L165041. Then 1ml (50 fmole) of 32P-labelled kB probe,
PPRE probe, or mutated PPRE probe, respectively, was added and
the incubation was carried out for additional 20minutes at room
temperature. The binding complexes were resolved on 5%
polyacrylamide gel in 0.5 TBE buffer (44.5mM Tris base, 44.5mM
boric acid, 1mM EDTA). Supershifts were performed by incubation
of the binding reaction with 2 mg anti-p65 antibodies (sc-109; Santa
Cruz Biotechnology, Santa Cruz, CA) or 1ml anti-PPARd rabbit
serum (Westergaard et al., 2003), respectively. In control experi-
ments, unlabelled kB oligonucleotide, PPRE oligonucleotide, or
mutated PPRE oligonucleotide, respectively, was used for competi-
tion, and added to the binding reaction together with the probes.
In-gel digestions and mass spectrometric analysis
The SDS–polyacrylamide gel containing the resolved protein from
the immunoprecipitation was stained with Coomassie blue and the
individually loaded lanes were cut into a number of pieces. The gel
pieces were washed four times with 50mM ammonium bicarbonate,
50% ethanol, and proteins were reduced by incubation with 10mM
dithiothreitol in 50mM ammonium bicarbonate for 30minutes at
561C. Alkylation of cysteines was performed by incubating the
samples with 50mM iodoacetamide in 50mM ammonium bicarbo-
nate for 20minutes at 251C in the dark. Gel pieces were washed two
times with 50mM ammonium bicarbonate, 50% acetonitrile, and
dehydrated with 100% acetonitrile. The gel pieces were rehydrated
in 12.5 ng ml1 trypsin (Sequencing Grade Modified Trypsin;
Promega, Madison, WI, USA) and incubated for 16 hours at 371C
for protein digestion. Supernatants were transferred to fresh types
and the remaining peptides were extracted using 30% acetonitrile in
3% trifluoroacetic acid (TFA) followed by dehydration with 100%
acetonitrile. The extracts were combined and desalted using RP-
C18Stage Tip columns and the eluted peptides were used for mass
spectrometric analysis. Proteins were identified by automated
database searching (Mascot Daemon; Matrix Science, Boston, MA)
against the Human International Protein Index protein sequence
database (European Bioinformatics Institute, www.ebi.ac.uk/IPI/).
Statistical analysis
Statistical evaluation of the data was performed using two-tailed
t-test for two samples. A P-value o0.05 was considered significant.
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